| DC10868 |
Cilofexor
Featured
|
Cilofexor (GS-9674, GS9674) is novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models. |
|
| DC9762 |
Emricasan
Featured
|
Emricasan (IDN-6556, PF-03491390) is a potent irreversible pan-caspase inhibitor. |
|
| DC9995 |
MGL-3196(Resmetirom)
Featured
|
MGL-3196 is a potent and highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia. |
|
| DC10173 |
Firsocostat(ND-630,GS-0976)
Featured
|
ND-630 is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively. |
|
| DC8390 |
Oltipraz
Featured
|
Oltipraz is a potent Nrf2 activator and a potent inducer of Phase II detoxification enzymes, most notably glutathione-S-transferase (GST). Phase 3. |
|
| DC10737 |
Tropifexor (LJN452)
Featured
|
Tropifexor (LJN452) is a highly potent non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). |
|
| DC9873 |
Selonsertib（GS-4997）
Featured
|
Selonsertib（GS-4997）is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. |
|
